ArticleObesity (Silver Spring, Md.)2025
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.
Article in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes.Clinical obesity · 2026Trial
- A Remote Program for Navigator- and Pharmacist-Led Management of Obesity Medications in Adults: Rationale, Design, and Implementation.Obesity science & practice · 2026Article
- Patient characteristics and early experiences with anti-obesity medications: the CAMP study.Frontiers in nutrition · 2026Article
- Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.Annals of internal medicine · 2025Article
- Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.Obesity (Silver Spring, Md.) · 2025Article
- Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveThe objective of this study was to describe the prevalence of obesity, obesity-related conditions (ORCs), and antiobesity medication (AOM) eligibility and prescribing practice among eligible patients in a large health care system.
methodsIn this cross-sectional analysis of the multicenter Mass General Brigham health care system (Boston, Massachusetts) spanning 2018 to 2022, adults eligible for AOMs (BMI ≥ 30 kg/m
resultsOf 2,469,474 adults (mean [SD], age 53 [19] years; 57% female; BMI 28.1 [6.3] kg/m
conclusionsAlthough nearly one-half of all patients in a large health care system were AOM-eligible by guidelines and regulatory labeling, only 1% of those who were eligible were prescribed AOMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.